The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vital to find effective and safe neutralizing antibodies and vaccines for COVID-19. The critical neutralizing domain (CND) that is contained in the receptor-binding domain (RBD) of the spike protein (S protein) could lead to a highly potent neutralizing antibody response as well as the cross-protection of other strains of SARS. By using RBD as an antigen, many neutralizing antibodies are isolated that are essential to the therapeutics of COVID-19. Furthermore, a subunit vaccine, which is based on the RBD, is expected to be safer than others, thus the RBD in the S protein is a more important target for vaccine development. In this review, we focus on neutralizing antibodies that are targeting RBD as well as the vaccine based on RBD under current development.
【저자키워드】 COVID-19, antibodies, SARS-CoV-2, Vaccines, RBD, 【초록키워드】 coronavirus disease, neutralizing antibody, Vaccine, Vaccine development, coronavirus, pandemic, cross-protection, S protein, Antigen, Neutralizing, Critical, Neutralizing antibody response, Coronavirus-2, strain, Safe, acute respiratory syndrome, subunit, global public health, domain, effective, caused, the spike protein, the RBD, the receptor-binding domain, the S protein, the WHO, the vaccine, expected, CND, 【제목키워드】 target, RBD of SARS-CoV-2,